Managers

Forget Brexit. U.K. remains atop European VC activity.

March Capital raises $302 mln for venture, opportunity funds

March Capital Partners has raised a $156.6 million second venture-capital fund and a $145.4 million second opportunity fund, according to a pair of filings with the SEC.

Mary Meeker swings for more than $1 bln for Bond

Revered venture capitalist Mary Meeker is seeking to raise $1.25 billion on a hard cap of $1.5 billion for a debut fund for her new venture capital firm, Bond, according to a report from Axios.

Mary Meeker's new firm Bond to raise $1.25 bln maiden fund: report

Triventures ARC targets $45 mln for healthcare seed fund

Triventures ARC, a venture capital arm of the ARC Innovation Center at Sheba Medical Center, an Israeli hospital, is seeking to raise $45 million for a fund focused on seed investments in healthcare innovations. Triventures, which is based in Herzliya, Israel and Menlo Park, California, will manage Triventures ARC.

Ablative Solutions takes in $77 mln Series D

Kalamazoo, Michigan and San Jose, California-based Ablative Solutions Inc, a company focused on treating hypertension, has secured $77 million in Series D funding. Gilde Healthcare and BioStar Ventures led the round with participation from other investors that included Michigan Accelerator Fund and Novus Biotechnology.

Tiburio Therapeutics grabs $31 mln Series A

Cambridge, Massachusetts-based Tiburio Therapeutics, a biopharmaceutical company newly launched by Cydan, has raised $31 million in Series A funding. The investors were New Enterprise Associates, Longitude Capital, Lundbeckfonden Ventures and Alexandria Venture Investments.

Prime Movers Lab collects over $22 mln for debut fund

Prime Movers Lab has raised over $22 million for its inaugural fund, according to an updated SEC filing. Jackson, Wyoming-based Prime Movers Lab invests in physics-powered startups founded by Prime Movers.

VC-backed StrideBio recruits Shah as CEO

Durham, North Carolina-based StrideBio Inc, a gene therapy company, has named Dr. Sapan Shah as CEO and a member of the company's board. Shah is a former chief executive at ARMGO Pharma and Ezose Sciences. StrideBio's backers include Hatteras Venture Partners, Takeda Ventures Inc, UCB Ventures and Alexandria Venture Investments LLC.

Connect Biopharmaceuticals snags $55 mln Series B

China-based Connect Biopharmaceuticals, a clinical-stage company that focuses on treating autoimmune diseases and inflammation, has closed $55 million in Series B financing. Advantech Capital led the round with participation from return backers Qiming Venture Partners, Northern Light Venture Capital and Cowin Venture. CEC Capital was financial adviser on the transaction.